Showing 1341-1350 of 1395 results for "".
- Retina Consultants of America Launches with Four Leading Partner Practiceshttps://modernod.com/news/retina-consultants-of-america-launches-with-four-leading-partner-practices/2477340/Retina Consultants of America (RCA), a physician management services organization recently formed by Webster Equity Partners, launched with four retina specialty practices. Practices include Retina Consultants of Houston, Retina Group of Florida, Long Island Vitreoretinal Consultants, and Retinal
- FOTO-TIA: Focus on the Eye May Discriminate TIA, Stroke vs Mimicshttps://modernod.com/news/foto-tia-focus-on-the-eye-may-discriminate-tia-stroke-vs-mimics/2477330/The retinal microvasculature can help differentiate mild stroke and transient ischemic attack (TIA) from a mimic presentation, helping physicians triage patients and initiate appropriate management, new evidence suggests, according to a report
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- Certain Chronic Illnesses Tied to Increased Crash Risk for Elderly Drivershttps://modernod.com/news/certain-chronic-illnesses-tied-to-increased-crash-risk-for-elderly-drivers/2477296/Some older drivers with chronic health problems may cut back on driving but still be at increased risk of crashes, a recent study suggests, as reported by Reuters. Meanwhile, other drivers with medical issues may also be at higher
- Positive Phase 3 Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in NEJMhttps://modernod.com/news/positive-phase-3-results-for-genentechs-satralizumab-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm/2477130/Genentech announced that data from SAkuraSky, a pivotal phase 3 study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the November 27, 2019 online issue of the New England Journal of Medicine (NEJM).
- Nidek Launches the YC-200 and YC-200 S Plus in the United Stateshttps://modernod.com/news/nidek-launches-the-yc-200-and-yc-200-s-plus-in-the-united-states/2477101/Nidek has announced that the FDA has issued 510(k) clearance for the YC-200 Ophthalmic YAG Laser System. The YC-200 includes the S plus model for Selective Laser Trabeculoplasty (SLT). With FDA clearance, the YC-200 and YC-200 S plus are now commercially available in the United States. The
- Sight Sciences: International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI Surgical System Predicate Device (VISCO360)https://modernod.com/news/sight-sciences-international-migs-study-confirms-long-term-safety-and-efficacy-of-the-omni-surgical-system-predicate-device-visco360/2477032/Sight Sciences announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s Canal using one of the OMNI
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- Registration Now Open for International Sports Vision Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-annual-conference/2476869/Registration is now open for Beyond 20/20, the 4th annual International Sports Vision Association (ISVA) conference, February 6-8, 2020, at the Bahia Resort Hotel in San Diego, California. “Sports Vision, the science of helping athletes reach peak levels of performance through t